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Abstract
Objectives Renal blood flow (RBF) has been shown to predict
disease progression in autosomal dominant polycystic kidney
disease (ADPKD). We investigated the feasibility and accura-
cy of phase-contrast RBF by MRI (RBFMRI) in ADPKD pa-
tients with a wide range of estimated glomerular filtration rate
(eGFR) values.
Methods First, we validated RBFMRI measurement using
phantoms simulating renal artery hemodynamics. Thereafter,
we investigated in a test-set of 21 patients intra- and inter-
observer coefficient of variation of RBFMRI. After validation,
we measured RBFMRI in a cohort of 91 patients and compared
the variability explained by characteristics indicative for dis-
ease severity for RBFMRI and RBF measured by continuous
hippuran infusion.
Results The correlation in flow measurement using phantoms
by phase-contrast MRI was high and fluid collection was high
(CCC=0.969). Technical problems that precluded RBFMRI
measurement occurred predominantly in patients with a lower
eGFR (34% vs. 16%). In subjects with higher eGFRs, vari-
ability in RBF explained by disease characteristics was similar
for RBFMRI compared to RBFHip, whereas in subjects with
lower eGFRs, this was significantly less for RBFMRI.
Conclusions Our study shows that RBF can be measured ac-
curately in ADPKD patients by phase-contrast, but this tech-
nique may be less feasible in subjects with a lower eGFR.
Key points
• Renal blood flow (RBF) can be accurately measured by
phase-contrast MRI in ADPKD patients.
• RBFmeasured by phase-contrast is associated with ADPKD
disease severity.
• RBF measurement by phase-contrast MRI may be less fea-
sible in patients with an impaired eGFR.
Keywords Renal blood flowmeasurement . Phase-contrast
MRI . Hippuran . ADPKD . Phantom
Introduction
Most autosomal dominant polycystic kidney disease
(ADPKD) subjects show progressive kidney function decline
and develop end-stage renal disease (ESRD) between their 4th
to 7th decade of life [1]. With renoprotective treatments
emerging, such as vasopressin V2-receptor antagonists and
somatostatin analogues [2, 3], it will be important to assess
disease severity. Especially those patients with a high likeli-
hood of disease progression towards ESRD will need treat-
ment. Assessing disease severity and prognosis in ADPKD is
not without difficulty. Glomerular filtration rate (GFR) may
not be the best measure in this respect, because GFR remains
within normal limits for an extended period of time [4]. There-
fore, total kidney volume (TKV) assessed by MRI has been
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investigated as an alternative [5]. TKV measurement is, how-
ever, laborious and the association between TKVand disease
severity is limited at an individual patient level. Renal blood
flow (RBF) has been proposed as a third marker to assess
disease severity [6]. A decrease in RBF flow paralleled TKV
growth in the observational CRISP cohort study [6] and is
thought to precede decline in GFR [7].
However, the value of RBF has been investigated in a sin-
gle study, using gadolinium-contrast to obtain a reference im-
age of the renal artery to position the phase-contrast perpen-
dicular to the vessel contour and included only ADPKD sub-
jects with a creatinine clearance > 70 ml/min [6, 7]. Confir-
mation, especially in subjects with lower kidney function, is
therefore needed. Moreover, a method without gadolinium
administration would be preferable to avoid the risks of devel-
oping gadolinium-associated contrast-induced nephropathy
[8] and nephrogenic systemic fibrosis [9, 10]. Besides MRI,
RBF can also be measured by infusion of para-aminohippuric
acid (RBFHip) [11, 12].
Given these considerations, the aim of the present study
was to investigate whether measurement of RBF by MRI
without using gadolinium contrast (RBFMRI) could be per-
formed accurately and precisely in a group of ADPKD pa-
tients with a wide range in kidney function. First, we validated
RBFMRI measurement using phantoms simulating renal artery
hemodynamics. Thereafter, we investigated in a test-set of
patients the intra- and inter-observer variability. After valida-
tion, we compared RBFMRI with RBFHip, and investigated
associations of RBFMRI and RBFHip with characteristics in-
dicative for disease severity in ADPKD subgroups.
Methods and Materials
Patient population
For this study, all consecutive patients with ADPKD visiting
our out-patient clinic from January 2007 until September 2012
were asked to participate. The diagnosis of APDKDwasmade
based upon the revised Ravine criteria [13]. Subjects were
considered ineligible if they received renal replacement ther-
apy, had undergone renal surgery, were unable to undergo
MRI, and had other systemic diseases or treatments potential-
ly affecting kidney function. One hundred forty six subjects
met these criteria, and were invited for an extensive, one-day
screening. This screening included, among others, an MRI
and assessment of effective renal plasma flow (ERPF), which
were used to measure RBFMRI and RBFHip. Thirteen patients
refused to participate and in thirteen patients, RBFMRI was not
measured due to logistical reasons, leaving 120 patients for the
present analyses. This study was conducted in accordance
with the guidelines of the Helsinki Declaration. All partici-
pants gave written informed consent.
Measurement and calculations
All participants collected at home a 24-hour urine sample the
day preceding the screening at our facility, in which albumin-
uria was measured. During the visit, blood pressure was mea-
sured (Dinamap) and fasting blood samples were drawn for
determination of osmolality, copeptin and creatinine. GFR
was estimated using the CKD-EPI (Chronic Kidney Disease
Epidemiology Collaboration) equation [14, 15]. MRI and
measurement of renal hemodynamic parameters were per-
formed per protocol on the same day.
Renal blood flow measured by MRI
Imaging was performed on a 1.5-Tesla Magnetom Avento
(Siemens, Erlangen, Germany). Two coils were placed on
the anterior and posterior abdominal walls directly over the
kidneys. Two fast, respiratory-triggered, coronal and transver-
sal T2-weighted image sets were acquired to determine the
kidney volumes [16]. To localize the renal arteries, coronal
and transversal data sets were scanned during the breath hold
using a T2-weighted TrueFISP sequence. RBF was assessed
with phase-contrast MRI (PC-MRI), using a two-dimensional
fast gradient echo phase-contrast sequence with retrospective
cardiac gating (30 cardiac phases) and flow compensation
[17]. Acquisition parameters TR/TE/FA were 43.6 ms/4 ms/
30 °. A single slice was positioned perpendicular to the renal
artery. Slice thickness was 5 mm, FOV was 32 cm, and the
number of phase-encoding steps was 260-384, depending on
patient size. Acquisition time was 150-160 seconds. The
encoding velocity (VENC) was 100 cm/s and flow acquisition
was obtained in the slice direction. Supplementary Figure 1
shows a representative sample of data recorded during the
cardiac cycle and shows a realistic renal arterial waveform.
RBFMRI measurement lasted between 150 and 160 seconds.
Flow analysis was performed using ARGUS flow software
(Siemens, Erlangen, Germany) for phase-contrast imaging.
Images were magnified to 5.0 and renal artery contours were
drawn manually on anatomical images to define the region of
interest for the corresponding phase-contrast images at all
phases of the cardiac cycle. The drawing of these contours
required 5-10 minutes per kidney. Flow rates of all renal ar-
teries (left, right and any additional arteries) were added to
calculate total RBFMRI. Flow measurements were judged
technically unsatisfactory when they met one or more of the
following criteria: indistinct vessel contour (blurred as a result
of motion), artefacts in the vessel area, ghosting (movement
artefacts), or non-physiologic, heterogeneous measurement or
weak signal [18]. TKVwas measured on T2-weighted coronal
images using Analyze Direct 8.0 (Analyze Direct, Inc., Over-
land Park, KS, USA) and divided by height. Intra- and inter-
observer coefficients of variation for TKV measurement were
1.8 and 2.3 %, respectively.
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Validation of flow measured by MRI in a phantom
Two flexible silicon phantoms, each representing the aorta and
two renal arteries perpendicular to the aorta (Elastrat, Geneva,
Switzerland) (Fig. 1) were used to assess accuracy of the PC-
MRI measurements. The four renal arteries in these two phan-
toms had diameters of 5, 6, 7 and 8 mm, representing the
normal range of renal artery diameters. The phantoms were
suspended in a container filled with water. An MRI-
compatible pump (Cardioflow 1000MR, Shelly Medical Im-
aging Technologies, London, Canada) was positioned proxi-
mally; one renal artery was connected to a container, the other
renal artery and distal aorta were connected to a reservoir
(Fig. 1). A mix of 40-% glycerol and 60-% purified water
was used as flow medium to mimic blood viscosity (~3.5
mPa/s) [19]. A synchronized trigger pulse signal was generat-
ed by the MRI to simulate electrocardiographic (ECG) gating
at a heart rate of 60 beats per minute. The flow in the phantom
was determined simultaneously by PC-MRI according to the
protocol described above and by fluid collection (volume
pumped through the renal artery was collected in a container).
These flow collections were considered the gold-standard
measure to evaluate the accuracy of the MR-calculated flow.
Importantly, the system was positioned in the horizontal plane
and the container was placed floating in the reservoir to pre-
vent any steady flow bias due to the principle of communicat-
ing vessels (Fig. 1). During our phantom experiment, the
pump was set at different flow rates (800, 1000, 1200 and
1400 ml/min) and acted as Bcardiac output^. In this phantom,
Bcardiac output^ is divided over two renal arteries and the
aorta. Thus, the blood flow rates in the phantom renal arteries
were dependent on the pump rates (Bcardiac output^) and the
diameters of the phantom renal arteries and aorta. Flow was
measured in one renal artery at a time, but several times to
assess reproducibility.
Variability of RBFMRI measurement
RBFMRI measurements were performed by two research phy-
sicians (ES and EM) whom were trained to perform RBFMRI
measurements. During their training period, they measured 60
RBFMRI values under supervision of an experienced MRI
technician (PK). Subsequently, they measured RBFMRI on 2
occasions, blinded to previous results, in 21 patients (i.e., 42
kidneys) to determine intra- and inter-observer variability.
RBF measured by 131I-hippuran
Measurement of renal hemodynamic parameters was per-
formed using a constant infusion method with 131I-hippuran
to measure ERPF [11, 20]. During these assessments, patients
were not water-loaded, but allowed to drink ad libitum. At
08.00 am, a priming solution of 0.04 mL/kg body weight
was administered, followed by a constant infusion of the tracer
at a rate depending on eGFR for 5.5 hours. After a stabilisation
period of 1.5 hours, two 2-hour clearance periods followed, in
which ERPF was measured as (I*V)/P, where I*V represents
the infusion of the tracer and P represents the tracer concen-
tration in plasma. Intra-subject day-to-day variability using
this method is 5 % [11]. RBFHip was calculated using the
formula ERPF/(1-hematocrit).
Statistical analysis
Lin’s concordance correlation coefficient (CCC) and Bland-
Altman analyses were used to assess agreement between the
gold standard fluid collection and the flow measured by MRI
in the phantom. Reproducibility was assessed by CCC, Bland-
Altman analyses and intra- and inter-observer coefficient of
variation (CV).
Subsequently, RBFMRI and RBFHip were measured in an
ADPKD patient cohort of which baseline characteristics were
calculated for the overall population and for participants with
an eGFR >70 and ≤70 ml/min*1.73m2, separately. Normality
was assessed by a Q-Q-plot. Normal distributed variables
were expressed as the mean ± standard deviation (SD), where-
as non-normal distributed variables were expressed as the me-
dian (interquartile range). Difference in baseline characteris-
tics between two eGFR subgroups was tested using a Chi-
square test for categorical data, and a Student’s t-test when
normally distributed or a Mann-Whitney test when not nor-
mally distributed.
Disease characteristics were correlated to RBFHip and to
RBFMRI in the overall cohort and in subcohorts stratified for
eGFR >70 and ≤70 ml/min*1.73m2. To investigate the best fit
for RBFHip and RBFMRI, we performed a stepwise backwards
Fig. 1 Schematic representation of the phantom used to study accuracy
and reliability of flow measured by MRI when compared to fluid
collection: A silicon phantom of the aorta and two renal arteries; B
pulsatile pump; C reservoir; and D container in which fluid output was
collected for flow measurement
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regression analysis. Clinically important disease characteris-
tics were entered and deleted stepwise from the model in order
of weakest association until a model with the best fit (i.e.,
adjusted R2) was obtained. Model discrimination was deter-
mined by bootstrapping (2000 times) to calculate the differ-
ence in adjusted R2 of two multivariate linear regression
models [21].
All analyses were performed with SPSS version 20.0
(SPSS Inc., Chicago, IL, USA). A two-sided p-value less than
0.05 was considered to indicate statistical significance.
Results
Validation of flow measured by MRI
Figure 2 shows a scatter-plot comparing pulsatile flow mea-
sured by fluid collection and flow measured by PC-MRI,
combined for all flow rates and vessel diameters. The 5-mm
diameter renal artery images were judged technically unsatis-
factory, because of artefacts in the vessel area and measure-
ment heterogeneity. An excellent agreement between flow
measured by the gold standard of fluid collection and by
PC-MRI was observed. The CCC for 6 to 8 mm was 0.969
(p < 0.001), indicating high agreement. Bland-Altman analy-
sis shows that flow measured by MRI on average
underestimated flow measured by fluid collection by 2.9 %
(Fig. 2). A significant correlation was noted between the mean
(flow measured by fluid collection and by MRI) and the ab-
solute difference between these two measures (r = -0.47, p =
0.004).
Reproducibility of RBFMRI measurement in a test-set
of ADPKD patients
Figure 3 shows the agreement between blood flow measured
by observers ES and EM in 21 ADPKD patients. The average
intra-observer CV was 2.3 % (ES 2.0 % and EM 2.6 %). The
estimated reliability, i.e., intra-class correlation coefficient, for
observers ES and EM were 0.997 and 0.995, respectively
(both p < 0.001). The inter-observer CV was 3.5 % with a
reliability coefficient of 0.991 (p < 0.001). In patients with an
eGFR >70 ml/min*1.73m2, the intra- and inter-observer CVs
were 1.5 and 3.5 %, respectively, whereas in patients with an
eGFR ≤70 ml/min*1.73m2, these values were 3.2 and 3.5 %,
respectively.
RBFMRI measurement in an ADPKD patient cohort
Out of the 120 patients, 29 (24 %) had RBF measurements
that were judged technically unsatisfactory, and these patients
were excluded for further analysis, leaving 91 ADPKD pa-
tients for analyses (in patients with an eGFR ≤70 and >70
ml/min*1.73m2, this held for 18 (34 %) and 11 (16 %) pa-
tients, respectively). The excluded patients had a significantly
lower eGFR and ERPF compared to the patients that could be
studied [eGFR 79.2 vs. 58.1 ml/min*1.73m2 (p = 0.001)], and
ERPF 263.5 vs. 201.7 ml/min*1.73m2 (p = 0.004). No signif-
icant difference in TKV was observed between the groups
(969 vs. 1526 mL/m, p = 0.28). The included patients were
relatively young with a mean age of 39.8 ± 11.4 years and
their eGFR ranged from 15 to 136 ml/min*1.73m2. Nine pa-
tients (9.9 %) had multiple renal arteries (one bilateral, seven
Fig. 2 Results of the phantom experiment. The upper panel shows a
scatter plot with flow assessed by fluid collection vs. measured by MRI.
The dotted line shows the line of identity. The lower panel shows a
corresponding Bland-Altman plot. The CCC was 0.977, 0.989 and
0.933 for the 6, 7 and 8 mm phantoms, respectively (p < 0.001 for all)
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unilateral and one unilateral with two additional renal arter-
ies). RBFMRI ranged from 244 to 1547 ml/min*1.73m
2. Right
artery RBFMRI was significantly higher than left artery
RBFMRI (456 vs. 358 ml/min*1.73m
2, p < 0.001). The
smallest renal artery diameter was 3.9 and the largest was
11.4 mm. The additional renal arteries had smaller diameters,
with a mean of 6 mm compared to 7 mm of ‘’single^ renal
arteries. As expected, RBF was significantly lower in patients
with lower eGFR whereas age, TKV and use of antihy-
pertensives were significantly higher in this subgroup
(Table 1). Figure 4 shows examples of PC-MRI flows that
were judged technically satisfactory and unsatisfactory.
Associations of RBFMRI and RBFHip with disease
characteristics.
RBFMRI correlated significantly with RBFHip (r = 0.81, p <
0.001), although RBFMRI was higher than RBFHip over the
entire range of RBFMRI. In univariate regression analyses,
both RBFMRI as well as RBFHip were positively correlated
with eGFR and urinary sodium excretion, and negatively with
age and TKV (Table 2). A stepwise backward multiple regres-
sionmodel showed that RBFHip and RBFMRI were significant-
ly and especially associated with eGFR (both <0.001). In the
whole group, the variability explained by the model for
RBFMRI was significantly lower than for RBFHip (adjusted
R2 = 0.61 and 0.77, respectively; p < 0.001). In patients with
an eGFR >70 ml/min*1.73m2, the adjusted R2 was not signif-
icantly different for RBFMRI than RBFHip (0.36 and 0.51,
respectively; p = 0.19), whereas in patients with an eGFR
≤70 ml/min*1.73m2, disease characteristics explained a
smaller fraction of variability in RBFMRI compared to RBFHip
(0.17 and 0.72, respectively; p < 0.001; Table 3).
In addition, we performed a sensitivity analysis in which
we excluded patients with additional renal arteries in order to
investigate whether multiple renal arteries caused methodo-
logical problems. Multiple renal arteries were found only in
patients with eGFR >70 ml/min*1.73m2. We found similar
variability in measurement of RBFMRI and MRIHip as in the
whole group (adjusted R2 = 0.63 and 0.77, respectively), and
the variability explained by the model increased slightly for
RBFMRI (adjusted R
2 = 0.42) and remained similar for RBFHip
(adjusted R2 = 0.53).
Discussion
In this study, we investigated whether measurement of RBF
byMRI without using gadolinium contrast (RBFMRI) could be
performed accurately and precisely. First, we validated
RBFMRI measurement using phantoms simulating renal artery
hemodynamics. Thereafter, we investigated in a test-set of
patients the reproducibility of RBFMRI. After validation, we
measured RBFMRI in a cohort of ADPKD patients and com-
pared RBFMRI and RBF measured by hippuran infusion with
characteristics indicative for disease severity.
In our phantom experiments, mimicking the clinical renal
hemodynamic profile, RBFMRI showed perfect agreement to
the gold-standard for flow measurement, i.e., fluid collection.
We observed no differences in accuracy in RBFMRI between
the Brenal arteries^ varying in diameter or between flow
Fig. 3 Intra-observer and inter-observer agreement of renal blood flow
(RBF) measurement (ml/min). AThe intra-class correlation coefficient for
observer Awas 0.997 and 0.995 for observer B (p < 0.001 for both; n = 21
ADPKD patients); the intra-observer coefficient of variation was 2.0 %
and 2.6 %, respectively. B The inter-observer coefficient of variation was
3.5 % with a reliability coefficient of 0.991 (p < 0.001)
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velocities, although it should be noted that measurement of
RBFMRI was not feasible in the Bartery^ with the smallest
diameter (5 mm). Our findings are in line with the values
obtained by Dambreville et al [19], who showed that steady
and pulsatile flow can be measured reliably in polyvinyl alco-
hol tubes with different diameters. These authors also experi-
enced difficulties in measuring MRI flow in tubes with small
diameters. In our test set of 21 patients, reproducibility was
high and comparable with values obtained in the literature
with contrast-measured RBF [6, 19]. These data indicate that
RBFMRI can be measured reliably in vitro and in vivo. In
patients without any additional renal arteries, we found similar
variability in measurement of RBFMRI and MRIHip compared
to all patients. These data indicate that the presence of addi-
tional renal arteries also does not influence the reliability of
RBF measurement.
We used MRI to measure RBFMRI in a cohort of ADPKD
patients. Our technical success rate was 76 %, which is com-
parable with previous literature on this method [18]. We com-
pared RBFMRI with RBFHip in these patients. It should be
noted that RBFHip is another indirect measurement of RBF.
RBFHip was lower compared to RBFMRI in patients with rel-
atively preserved as well as impaired kidney function. It is
known that RBFHip underestimates RBF, because the extrac-
tion of hippuran by tubular cells is not 100 % and dependent
on kidney function [12]. In two previous studies, it was shown
that RBFMRI correlated well with RBF determined by
clearance of para-amino-hippurate (r = 0.94 and r = 0.93,
respectively) [22, 23]. These studies used healthy subjects.
In the present study we applied hippuran instead of para-
amino-hippurate [12]. We showed that RBFMRI correlated
well with RBFHip (r = 0.90) and that RBFMRI was associated
with anatomical, hemodynamic and laboratory parameters in-
dicating disease severity. This corroborates the findings by the
CRISP consortium that found the same associations and addi-
tionally described that RBFMRI predicted kidney function de-
cline [6]. Measurement of RBF can, therefore, be important to
assess disease severity, to predict prognosis and potentially
also act as a surrogate endpoint to assess the efficacy of
renoprotective interventions early in the disease. RBF could
also be used in combination with GFR to assess the filtration
fraction [24].
Although on average we showed that RBF could be mea-
sured reliably byMRI without using contrast, there are a num-
ber of issues rendering such measurement less feasible in
ADPKD patients with impaired kidney function. First,
RBFMRI measurement in the smallest phantom artery (5
mm), which is a surrogate for more severe ADPKD, was not
possible. Second, in the phantom experiment, we found a
significant correlation between mean flow and difference in
flow measured by MRI and fluid collection, with a larger
difference in the lower flow range. This indicates that system-
atic bias increases at the lower flow range. Third, variability
was higher in patients with a low eGFR than in patients with a
Table 1 Baseline characteristics of the 91 ADPKD patients included in the present study
All Stratified according to eGFR (ml/min*1.73m2)
>70 ≤70 p-value
Number of participants 91 57 34
Age (y) 39.8 ± 11.4 34.9 ± 8.5 48.0 ± 11.2 <0.001
Male (%) 58.2 % 54.4 % 64.7 % 0.3
Diastolic BP (mm Hg) 79.9 ± 9.6 79.9 ± 9.7 79.9 ± 9.5 0.9
Systolic BP (mm Hg) 129.2 ± 11.9 129.4 ± 12.0 128.9 ± 12.0 0.8
Antihypertensive medication (%) 79.1 % 70.2 % 94.1 % 0.007
Plasma Osmolality (mOsm/kg) 288 ± 6.7 286.5 ± 6.5 290.8 ± 6.2 0.004
Serum Copeptin (pmol/l) 6.5 (3.0-14.7) 4.4 (2.7 – 8.8) 13.2 (8.0 – 18.1) <0.001
eGFR (ml/min*1.73m2) 79.2 ± 28.8 98.1 ± 15.3 47.5 ± 14.7 <0.001
Renal blood flow (MRI) (ml/min*1.73m2) 814 ± 302 973.6 ± 243 545 ± 174 <0.001
Renal blood flow (hippuran) (ml/min*1.73m2) 440 ± 157 533 ± 109 285 ± 86.7 <0.001
Total kidney volume (mL/m) 852 (251 – 1272) 729 (483 – 1083) 1167 (748 – 1434) 0.003
24h urinary volume (mL) 2255 ± 767 2173 ± 842 2392 ± 613 0.2
24h urinary sodium excretion (mmol) 173 ± 71 184 ± 74 157 ± 65 0.1
24h urinary albumin excretion (mg) 36.3 (14.2 - 117.8) 36.3 (14.8 – 88.0) 42.4 (13.3 – 178.4) 0.4
Note: Unless otherwise indicated, values for categorical variables are given as percentages; values for continuous variables are given as the mean ±
standard deviation (if parametric) or median [interquartile range] if nonparametric. P-values indicate differences between >70 ml/min*1.73m2 and ≤70
ml/min*1.73m2 .
P-values are calculated by t-tests when normally distributed and by Mann-Whitney U tests when non-normally distributed. Abbreviations: ADPKD,
autosomal dominant polycystic kidney disease; BP, blood pressure; eGFR, estimated glomerular filtration rate
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high eGFR. Fourth, RBFMRI measurement in patients with
lower eGFRs resulted less often in interpretable images.
MRI images were judged technically unsatisfactory in 34 %
of patients with an eGFR ≤70 vs. in 16 % of patients with an
eGFR >70 ml/min*1.73m2. Fifth, in subjects with a lower
eGFR, only a small fraction of variability in RBFMRI was
explained by disease characteristics. We speculate that due
to the lower RBF in smaller renal arteries the phase-contrast
measurement may give a (too) weak signal, causing the lower
success rate. Two methods could be used to overcome this
problem. The spatial resolution could be increased or the
VENC could be adjusted. However, for this study, we used
the protocol of the CRISP consortium [6, 7, 19] with pre-
determined variables (FOV 32 cm, slide thickness 5 mm,
VENC of 100cm/s) as to maintain the protocol and to compare
results without bias. In addition, renal arteries with larger
Fig. 4 Phase-contrast magnetic
resonance angiogram without
gadolinium of the renal arteries in
ADPKD. a The phase-contrast
angiogram was performed
perpendicular to the renal artery
on the coronal image b Cross-
sectional image through the renal
artery that was judged technically
satisfactory and c unsatisfactory
to measure renal blood flow,
because of indistinct vessel
jcontour (blurred as a result of
motion)
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Table 2 Associations of renal blood flow (ml/min*1.73m2) measured byMRI or hippuran with characteristics indicative for disease severity in ADPK
D (n = 91)
Univariate analyses Multivariate analyses
MRI Hippuran MRI Hippuran
r p r p Std β p Std β p
Adjusted R2 0.61* 0.77*
Age (years) -0.56 <0.001 -0.58 <0.001 -0.10 0.17
Female vs male sex (1 or 0) 0.096 0.37 -0.06 0.58 -0.11 0.09
Weight (kg) -0.21 0.05 -0.13 0.23 -0.09 0.15
Systolic blood pressure (mmHg) -0.07 0.54 0.12 0.25 -0.09 0.16 0.07 0.21
Antihypertensive drugs (Yes=1) -0.15 0.16 -0.18 0.08 0.13 0.08 0.11 0.05
Plasma osmolality (mOsm/kg) -0.30 0.004 -0.14 0.18 0.09 0.14
Log Copeptin (pmol/l) -0.24 0.02 -0.16 0.13 -0.07 0.31
eGFR (ml/min*1.73m2) 0.77 <0.001 0.86 <0.001 0.82 <0.001 0.88 <0.001
Ln TKV/h (ml/m) -0.22 0.04 -0.23 0.03
24h urine volume (mL) -0.17 0.10 -0.10 0.33 0.07 0.25
Urinary sodium excretion (mmol/24h) 0.23 0.03 0.30 0.003
Ln Urinary albumin excretion (mg/24h) 0.04 0.73 -0.02 0.86 0.14 0.04
TKV/h and UAE were natural logarithm transformed and copeptin was log transformed. Abbreviations: eGFR, estimated glomerular filtration rate;
TKV/h, total kidney volume/height. * Model discrimination assessed by bootstrapping (2000 times), p-value < 0.001
Table 3 Multivariate
associations of renal blood flow
(ml/min*1.73m2) measured by
MRI or hippuran with
characteristics indicative for
disease severity in patients
stratified for kidney function
eGFR >70 ml/min*1.73m2 MRI Hippuran
N = 57 Std β p Std β p
Adjusted R2 0.36 0.51
Age (years) -0.26 0.07
Female vs male sex (1 or 0) -0.36 0.005
Weight (kg) -0.13 0.23 -0.20 0.08
Antihypertensive drugs (Yes = 1) 0.19 0.01 0.17 0.11
Plasma osmolality (mOsm/kg) 0.14 0.20
eGFR (ml/min*1.73m2) 0.66 <0.001 0.60 <0.001
24h Urine volume (mL) 0.12 0.30 0.28 0.02
Ln (Urinary albumin excretion mg/24h) 0.24 0.03 0.16 0.13
eGFR ≤ 70 ml/min*1.73m2 MRI Hippuran
N = 34 Std β p Std β p
Adjusted R2 0.17* 0.72*
Female vs male sex (1 or 0) -0.30 0.15
Weight (kg) -0.21 0.24
Plasma osmolality (mOsm/kg) -0.23 0.20 0.10 0.31
Log (Copeptin pmol/l) -0.19 0.30 -0.25 0.03
eGFR (ml/min*1.73m2) 0.38 0.03 0.89 <0.001
24h Urine volume (mL) -0.22 0.20 -0.23 0.02
Ln (Urinary albumin excretion mg/24h) 0.17 0.14
* Model discrimination assessed by bootstrapping (2000 times), p-value < 0.001.
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diameters allow better phase-contrast positioning and easier
measurement of the flow. Notwithstanding these observations,
we think that this does not necessarily disqualify the use of
RBFMRI measurement for ADPKD staging and risk classifi-
cation. The clinical need for risk classification in this patient
group is especially present early in the disease, when GFR
remains within the normal limits for an extended period of
time [1]. At a later stage of the disease, when kidney function
starts to decline, eGFR in association with age can be used as a
parameter to assess disease severity and prognosis. It should
be stated that in patients with an eGFR >70 ml/min*1.73 m2,
gadolinium-enhanced techniques can also be used to measure
RBF, because in this patient subgroup there is a low risk of
toxicity. Lastly, there are other unenhanced techniques to mea-
sure flow, such as arterial spin labelling [25], but this tech-
nique is especially useful to measure regional variations in
renal perfusion, and investigating this technique was beyond
the scope of the present study. Of note, a pilot study showed
no difference for RBF values between arterial spin labelling
and RBFMRI measurement [26].
Limitations of our study are, first, that we studied renal
hemodynamical parameters in a cross-sectional setting. There-
fore, we were not able to investigate associations with disease
progression. Second, this study assessed reliability and accuracy
of RBFMRI using a phantom simulating the clinical situation.
However, it lacks a gold standard method for RBF measurement
in vivo. Such a method would necessitate a flow probe directly
introduced in the renal arteries, which, because of its invasive
character, is not feasible. We, therefore, assessed reliability of
RBFMRI in an indirect way, by studying the degree of variability
of RBFMRI that was explained by accepted characteristics of
ADPKD severity, and by comparing this with the degree of
variability of RBFHip explained by the same disease characteris-
tics. Strengths of our study were that we measured RBFMRI and
ERPF by gold-standard techniques on the same day. These mea-
surements were performed in a relatively large, well-phenotyped
cohort of ADPKD patients with relatively preserved as well as
impaired kidney function. Furthermore, our method avoids use
of gadolinium, which is important because of the potential side
effects of this contrast agent in patients with kidney dysfunction
[27].
In conclusion, our study shows that in ADPKD patients, RBF
can be measured by MRI accurately and reliably without using
gadolinium contrast, but that assessment of RBF by PC-MRI
may be less feasible in patients with impaired kidney function.
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